By Tian Johnson, African Alliance, and Fatima Hassan, Well being Justice Initiative
South Africa is being requested to have a good time a breakthrough that hasn’t occurred but. A plan to ship lenacapavir (a groundbreaking HIV prevention injection) to roughly 400,000 individuals in our nation has been framed as a turning level within the nation’s HIV response. However the entire donated doses will not be but in hand, the rollout has not begun at scale, and the hole between promise and supply stays large.
The federal government’s current name underneath the auspices of the South African Nationwide AIDS Council (SANAC) for expressions of curiosity to fabricate lenacapavir domestically is being framed as a decisive step ahead. In actuality, it’s the starting of an extended and unsure course of that uncritically palms immense energy to the monopoly holder of lenacapavir: Gilead Sciences.
Based on the Expression of Curiosity, revealed on 5 March 2026, native manufacturing corporations are invited to use (once more). SANAC will shortlist and assess the proposals after which pursue license negotiations with Gilead. Provided that these negotiations succeed with Gilead straight will a license be granted on phrases that aren’t but outlined and never managed by South Africa. Solely then can manufacturing start. Solely after that can regulatory approval be sought. Opposite to what UNITAID has urged, this, in actuality, isn’t prone to happen inside a 12 months (the opposite 6 licensees will not be but in the marketplace, these licenses have been issued some time again, and never a single one is in the marketplace but, together with the Egyptian one).
The HIV epidemic is not going to respect this timeline. South Africa continues to file lots of of latest HIV infections day-after-day. But the response being constructed strikes on the tempo of committees, approvals, negotiations, and conditional agreements. There isn’t a binding timeline for when domestically produced doses will attain those that want them probably the most.
No dedication on what number of doses will likely be produced every year.
No readability on what they may price.
No readability on whether or not sufferers exterior of state amenities can entry them too, and the way.
No readability on whether or not South Africa will likely be permitted to produce nations exterior of Africa that Gilead excluded from earlier licensing preparations.
In an energetic epidemic, these shortfalls may have actual penalties.
Worryingly, the Expression of Curiosity is notably silent on whether or not SANAC’s shortlisting choices are binding. If, as has been urged by insiders, ultimate approval rests with Gilead Sciences, enabling them to veto any shortlisting by SANAC, then the method dangers decreasing nationwide actors to facilitators fairly than decision-makers.
A producing plan with out management
The SANAC Expression of Curiosity course of makes one factor clear: the result of this initiative doesn’t sit in South Africa’s palms, regardless of the entire guarantees of multi-stakeholder overview and engagement, and untimely celebratory information headlines. The looming shadow of Gilead, whose monitor file prioritises income over entry, could be very a lot staring us within the face.
Native manufacturing doesn’t equal independence. On this case, it would depend upon whether or not a seventh voluntary licence is certainly granted, on what phrases, and on entry to data and inputs that stay managed elsewhere. At no level within the course of is there an enforceable assure that native manufacturing will really proceed, not to mention on the required scale.
Subscribe to our e-newsletter
This association additionally dangers decreasing SANAC to an administrative clearing home. It convenes, consults, and coordinates, but it surely doesn’t make choices. The license, if granted, will likely be issued underneath phrases set by Gilead Sciences, which is able to keep management over pricing, volumes, and the tempo of scale-up. Consequently, the South African authorities is left implementing a programme whose most important parameters are determined elsewhere. That’s not a partnership.
South Africa might host the factories and assemble the product. It could carry the burden of supply. However with out authority over all features of licensing, together with pricing and scale, it doesn’t management the result.
This creates a peculiar type of progress wherein South Africa prepares to construct capability with out figuring out whether or not it is going to be allowed to make use of it totally. It invests in a future provide chain that it doesn’t but govern. It alerts ambition whereas accepting uncertainty at each vital level.
This dynamic has outlined the connection between African nations and world well being innovation for many years. The work occurs right here: the trials, the info, the mobilisation of communities, the constructing of supply programs. When a breakthrough emerges, the continent is (possibly, ultimately) invited to take part in its manufacturing, however not often to find out its phrases. We noticed this in the course of the COVID-19 pandemic with drug corporations of their native licensing preparations, even dictating the top vacation spot for domestically manufactured provides. Lenacapavir is starting to observe that very same script.
Capability with out ensures
The native licensing announcement and proposal give attention to functionality: infrastructure, compliance, and technical readiness. It asks who can produce. It doesn’t reply who will likely be protected. There aren’t any binding commitments but on manufacturing volumes. No indication of how many individuals will really obtain it every year. No targets linked to the quantity required to interrupt transmission. There may be additionally no outlined worth, no ceiling, no mechanism to make sure that domestically produced doses will likely be inexpensive at scale or assurances that, aside from South Africa and the area, different nations unnoticed by Gilead that want entry will profit from South African manufacturing too.
With out these parts, manufacturing doesn’t routinely translate into fairness or entry. It might simply as simply reproduce shortage underneath a special label.
The query isn’t whether or not a licence will likely be signed, however what that licence really ensures and delivers. The South African authorities may have taken obligatory measures, however thus far, it has chosen to not. So now the programme particulars will likely be as much as Gilead’s attorneys, not within the palms of the Well being Minister, SANAC, and even the President.
That is nothing new. Too typically, voluntary license preparations introduced as breakthroughs fail to translate into entry. They lack enforceable timelines, assured volumes, actual worth commitments, and significant expertise switch. They supply false hope.
A licence that shifts manufacturing with out shifting energy modifications little or no. The take a look at is easy: does it scale back infections within the subsequent two years, or does it defer them?
The query South Africa has not answered
There’s a strategy to learn the present second as pragmatic. Manufacturing takes time, programs have to be constructed and requirements have to be met. All of that is true. However pragmatism has a method of hardening into acceptance. And acceptance, in a rustic with South Africa’s burden of illness, worsened by the U.S. authorities’s punitive HIV funding cuts, carries a concrete price.
South Africa is doing the work required to make a life-saving expertise out there. However whether or not that work will lead to entry on the scale and velocity required to interrupt HIV transmission isn’t one thing it could actually but assure. That’s the contradiction on the coronary heart of this effort. A rustic on the centre of the HIV epidemic is constructing a system it doesn’t totally management, on a timeline it doesn’t set, for an consequence it can not but safe.
This isn’t how epidemics are ended.
______________________________________________________________
Tian Johnson is the founder and strategist of the Pan-African well being justice advocacy group, African Alliance. Fatima Hassan, is a South African human rights lawyer and social justice activist, and founding father of the Well being Justice Initiative. That is half 2 of a two-part opinion collection by Johnson and Hassan inspecting the hole between scientific breakthrough and public well being influence in South Africa’s response to HIV with the arrival of long-acting lenacapavir.
The views and opinions expressed on this opinion piece are these of the writer, who isn’t employed by Well being-e Information. Well being-e Information is dedicated to presenting numerous views to counterpoint public discourse on health-related points.
